| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
40,701 |
36,108 |
$10.17M |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
2,941 |
2,667 |
$621K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
38,497 |
29,723 |
$51K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,562 |
12,295 |
$17K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,852 |
2,161 |
$3K |
| 0012A |
|
115 |
79 |
$2K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,342 |
1,239 |
$2K |
| 90686 |
|
3,189 |
2,606 |
$1K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,334 |
1,163 |
$854.50 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
305 |
284 |
$721.92 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,403 |
1,883 |
$648.29 |
| 90746 |
|
516 |
364 |
$545.56 |
| 99215 |
Prolong outpt/office vis |
114 |
68 |
$501.54 |
| 90715 |
|
583 |
506 |
$389.21 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,017 |
2,352 |
$335.26 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,122 |
2,160 |
$326.30 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
209 |
182 |
$325.84 |
| 90688 |
|
448 |
421 |
$229.23 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
163 |
122 |
$210.95 |
| 85018 |
|
1,720 |
1,311 |
$198.35 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
613 |
490 |
$172.71 |
| 90656 |
|
358 |
252 |
$152.99 |
| 92552 |
|
1,378 |
1,075 |
$138.97 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
37 |
25 |
$137.80 |
| 90674 |
|
30 |
29 |
$98.46 |
| 90716 |
|
194 |
166 |
$75.60 |
| 0011A |
|
57 |
49 |
$39.15 |
| 90670 |
|
290 |
271 |
$37.80 |
| 90707 |
|
185 |
157 |
$37.80 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
150 |
148 |
$33.63 |
| 82948 |
|
846 |
766 |
$21.32 |
| 82962 |
|
1,045 |
709 |
$20.76 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
25 |
24 |
$17.56 |
| 81002 |
|
88 |
85 |
$17.32 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
21 |
21 |
$13.26 |
| 86580 |
|
172 |
160 |
$10.53 |
| 90633 |
|
53 |
50 |
$9.45 |
| 90685 |
|
64 |
62 |
$9.45 |
| 90658 |
|
39 |
39 |
$9.45 |
| 90696 |
|
38 |
26 |
$9.45 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
394 |
383 |
$7.64 |
| 81003 |
|
301 |
274 |
$3.92 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
28 |
27 |
$3.56 |
| 1159F |
|
13,896 |
12,234 |
$0.00 |
| 1160F |
|
12,463 |
11,015 |
$0.00 |
| 3078F |
|
2,643 |
2,451 |
$0.00 |
| 90653 |
|
18 |
18 |
$0.00 |
| 3077F |
|
257 |
242 |
$0.00 |
| 90734 |
|
44 |
29 |
$0.00 |
| 3046F |
|
14 |
13 |
$0.00 |
| 90649 |
|
81 |
67 |
$0.00 |
| 81025 |
|
82 |
66 |
$0.00 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
57 |
44 |
$0.00 |
| 99442 |
|
25 |
25 |
$0.00 |
| 3074F |
|
2,061 |
1,941 |
$0.00 |
| 3079F |
|
603 |
571 |
$0.00 |
| 3008F |
|
7,090 |
6,481 |
$0.00 |
| G9964 |
Patient received at least one well-child visit with a pcp during the performance period |
56 |
56 |
$0.00 |
| 90647 |
|
89 |
79 |
$0.00 |
| 3075F |
|
613 |
587 |
$0.00 |
| 90732 |
|
47 |
36 |
$0.00 |
| 91301 |
|
86 |
82 |
$0.00 |
| 90723 |
|
74 |
63 |
$0.00 |
| 3044F |
|
76 |
75 |
$0.00 |
| 90677 |
|
21 |
12 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
19 |
19 |
$0.00 |
| 90680 |
|
16 |
13 |
$0.00 |